Recordati announced strong 2026 first half results
Revenue rose 6.6%, EBITDA 8.8%, and adjusted net income 6.7%, plus a new licensing deal for a neurological condition.
See the latest news and media coverage for Recordati. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company developing and commercialising medicines
recordati.comLast updated
In short: Recordati received a takeover offer from CVC and GBL while reporting strong financial growth and securing strategic global partnerships.
Revenue rose 6.6%, EBITDA 8.8%, and adjusted net income 6.7%, plus a new licensing deal for a neurological condition.
The report provides financial results and operational highlights for the six months ended June 30, 2026
It follows Article 36 of the Italian Issuers' Regulation regarding mandatory offers.
The statement relates to the voluntary takeover bid for all Recordati shares launched by Respighi BidCo.
Barclays lifted its Recordati target price to EUR 55 from EUR 50 on September 8, 2026, a 10 percent increase in the bank's valuation call...
Upon deal completion, group will acquire company’s oncology product portfolio for $846 million...
In May, CVC teamed up with Belgium’s Groupe Bruxelles Lambert and other investors to launch the €51.29-a-share tender offer ...
(Il Sole 24 Ore Radiocor) - Milan, 10 Aug - The European Commission has authorized, pursuant to the EU regulation on concentrations...
Track Recordati and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Recordati and other trending companies.